ECSP14013211A - Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes - Google Patents
Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetesInfo
- Publication number
- ECSP14013211A ECSP14013211A ECSP14013211A ECSP14013211A EC SP14013211 A ECSP14013211 A EC SP14013211A EC SP14013211 A ECSP14013211 A EC SP14013211A EC SP14013211 A ECSP14013211 A EC SP14013211A
- Authority
- EC
- Ecuador
- Prior art keywords
- diabetes
- tetrahydroquinoline
- useful
- treatment
- new derivative
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524462P | 2011-08-17 | 2011-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP14013211A true ECSP14013211A (es) | 2014-03-31 |
Family
ID=46690732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP14013211 ECSP14013211A (es) | 2011-08-17 | 2014-02-17 | Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8431706B2 (enExample) |
| EP (1) | EP2744806B1 (enExample) |
| JP (1) | JP5903162B2 (enExample) |
| KR (1) | KR101570624B1 (enExample) |
| CN (1) | CN103687856B (enExample) |
| AP (1) | AP3589A (enExample) |
| AR (1) | AR087451A1 (enExample) |
| AU (1) | AU2012295372A1 (enExample) |
| BR (1) | BR112014003079A2 (enExample) |
| CA (1) | CA2843474C (enExample) |
| CL (1) | CL2014000357A1 (enExample) |
| CO (1) | CO6880069A2 (enExample) |
| CR (1) | CR20140052A (enExample) |
| DO (1) | DOP2014000018A (enExample) |
| EA (1) | EA022165B1 (enExample) |
| EC (1) | ECSP14013211A (enExample) |
| ES (1) | ES2578165T3 (enExample) |
| GT (1) | GT201400022A (enExample) |
| IL (1) | IL230635A (enExample) |
| IN (1) | IN2014MN00191A (enExample) |
| MA (1) | MA35351B1 (enExample) |
| MX (1) | MX2014001832A (enExample) |
| PE (1) | PE20140831A1 (enExample) |
| PH (1) | PH12014500366A1 (enExample) |
| SG (1) | SG11201401793PA (enExample) |
| TN (1) | TN2014000058A1 (enExample) |
| TW (1) | TWI537262B (enExample) |
| UA (1) | UA110983C2 (enExample) |
| WO (1) | WO2013025424A1 (enExample) |
| ZA (1) | ZA201400705B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
| US11964938B2 (en) | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2020283307B2 (en) | 2019-05-31 | 2025-03-06 | Hyundai Pharm Co., Ltd. | Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| EP4052790A4 (en) * | 2019-10-31 | 2023-12-27 | China Petroleum & Chemical Corporation | SUPPORTED CATALYST, ITS PREPARATION METHOD AND ITS APPLICATION |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
| KR102699076B1 (ko) * | 2021-04-01 | 2024-08-27 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
| CN115317484B (zh) * | 2022-08-26 | 2023-07-18 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用 |
| CN115671105B (zh) * | 2022-11-22 | 2023-10-27 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| IL157093A0 (en) * | 2001-03-27 | 2004-02-08 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| CA2558585C (en) | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US7517910B2 (en) * | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| AR078948A1 (es) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
-
2012
- 2012-08-03 TW TW101128102A patent/TWI537262B/zh not_active IP Right Cessation
- 2012-08-03 AR ARP120102845A patent/AR087451A1/es unknown
- 2012-08-09 SG SG11201401793PA patent/SG11201401793PA/en unknown
- 2012-08-09 CN CN201280036072.0A patent/CN103687856B/zh not_active Expired - Fee Related
- 2012-08-09 ES ES12748334.5T patent/ES2578165T3/es active Active
- 2012-08-09 AP AP2014007436A patent/AP3589A/xx active
- 2012-08-09 UA UAA201401073A patent/UA110983C2/uk unknown
- 2012-08-09 MX MX2014001832A patent/MX2014001832A/es unknown
- 2012-08-09 JP JP2014526078A patent/JP5903162B2/ja not_active Expired - Fee Related
- 2012-08-09 US US13/570,342 patent/US8431706B2/en not_active Expired - Fee Related
- 2012-08-09 WO PCT/US2012/050051 patent/WO2013025424A1/en not_active Ceased
- 2012-08-09 CA CA2843474A patent/CA2843474C/en not_active Expired - Fee Related
- 2012-08-09 PH PH1/2014/500366A patent/PH12014500366A1/en unknown
- 2012-08-09 PE PE2014000218A patent/PE20140831A1/es not_active Application Discontinuation
- 2012-08-09 EP EP12748334.5A patent/EP2744806B1/en active Active
- 2012-08-09 BR BR112014003079A patent/BR112014003079A2/pt not_active IP Right Cessation
- 2012-08-09 EA EA201490269A patent/EA022165B1/ru not_active IP Right Cessation
- 2012-08-09 KR KR1020147003634A patent/KR101570624B1/ko not_active Expired - Fee Related
- 2012-08-09 AU AU2012295372A patent/AU2012295372A1/en not_active Abandoned
-
2013
- 2013-01-30 CR CR20140052A patent/CR20140052A/es unknown
-
2014
- 2014-01-23 IL IL230635A patent/IL230635A/en not_active IP Right Cessation
- 2014-01-28 DO DO2014000018A patent/DOP2014000018A/es unknown
- 2014-01-29 ZA ZA2014/00705A patent/ZA201400705B/en unknown
- 2014-01-30 IN IN191MUN2014 patent/IN2014MN00191A/en unknown
- 2014-02-10 TN TNP2014000058A patent/TN2014000058A1/en unknown
- 2014-02-13 GT GT201400022A patent/GT201400022A/es unknown
- 2014-02-13 MA MA36755A patent/MA35351B1/fr unknown
- 2014-02-13 CL CL2014000357A patent/CL2014000357A1/es unknown
- 2014-02-14 CO CO14032116A patent/CO6880069A2/es active IP Right Grant
- 2014-02-17 EC ECSP14013211 patent/ECSP14013211A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP14013211A (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| PH12017500493A1 (en) | Combination therapy | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| ECSP12011930A (es) | Nuevos compuestos de espiropiperidina | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| CR20140325A (es) | Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- | |
| NZ730816A (en) | Quinoline carboxamides for use in the treatment of multiple myeloma | |
| MX2015005739A (es) | Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2. | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| MX2014005538A (es) | 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1). | |
| UY33973A (es) | Métodos de tratamiento dirigido de degeneración lobular frontotemporal. | |
| WO2014147578A3 (en) | Antibacterial compounds against drug resistant bacteria | |
| MX2014004853A (es) | 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos. | |
| TN2014000307A1 (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors | |
| ECSP14011506A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors |